Last reviewed · How we verify
Medroxyprogesterone Acetate 10 MG
At a glance
| Generic name | Medroxyprogesterone Acetate 10 MG |
|---|---|
| Also known as | Provera |
| Sponsor | Ginefiv |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency (NA)
- Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (PHASE4)
- Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features (PHASE2, PHASE3)
- Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A. (PHASE4)
- Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medroxyprogesterone Acetate 10 MG CI brief — competitive landscape report
- Medroxyprogesterone Acetate 10 MG updates RSS · CI watch RSS
- Ginefiv portfolio CI